Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Public biotech 2009—the numbers

Nature Biotechnology volume 28, pages 793–799 (2010)Cite this article

Subjects

An Erratum to this article was published on 13 October 2010

This article has been updated

The public biotech sector sustained more losses in 2009, but the year ended on a positive note, and the industry has regained its footing.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Global biotech industry financing.
Figure 2: Global biotech initial public offerings.
Figure 3: Public biotech company revenue, R&D spending, profits and number of employees by market cap.

Change history

  • 13 October 2010

    In the version of this article initially published, in Table 6, Acorda was said to have entered into a licensing agreement with Bayer. In fact, Acorda entered into a licensing agreement with Biogen, not Bayer. The error has been corrected in the HTML and PDF versions of the article.

Acknowledgements

The authors would like to acknowledge the insight of G. Giovannetti and G. Jaggi in crafting this article.

Author information

Authors and Affiliations

  1. Data retrieval for this article was by Ernst & Young (Boston) with additional reporting by Riku Lähteenmäki.,

    Riku Lähteenmäki

  2. Brady Huggett is business editor at Nature Biotechnology.,

    Brady Huggett

  3. John Hodgson is editor-at-large at Nature Biotechnology.,

    John Hodgson

  4. Riku Lähteenmäki is a freelance writer in Turku, Finland.,

    Riku Lähteenmäki

Authors
  1. Brady Huggett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Hodgson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Riku Lähteenmäki
    View author publications

    You can also search for this author in PubMed Google Scholar

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huggett, B., Hodgson, J. & Lähteenmäki, R. Public biotech 2009—the numbers. Nat Biotechnol 28, 793–799 (2010). https://doi.org/10.1038/nbt0810-793

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0810-793

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research